Besifloxacin Ophthalmic Suspension, 0.6%: a Novel Topical Fluoroquinolone for Bacterial Conjunctivitis

Evaluation of the Effect of Bacterial Efflux Pumps on the Antibacterial Activity of the Novel Fluoroquinolone Besifloxacin

(2014) D.L. Shinabarger et al.   JOURNAL OF CHEMOTHERAPY

Monitoring Antibiotic Resistance in Ocular Microorganisms: Results From the Antibiotic Resistance Monitoring in Ocular MicRorganisms (ARMOR) 2009 Surveillance Study

(2011) Wolfgang Haas et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

Topoisomerase Mutations That Are Associated with High-Level Resistance to Earlier Fluoroquinolones in Staphylococcus aureus Have Less Effect on the Antibacterial Activity of Besifloxacin

(2011) Christine M. Sanfilippo et al.   CHEMOTHERAPY

Efficacy and Tolerability of Besifloxacin Ophthalmic Suspension 0.6% Administered Twice Daily for 3 Days in the Treatment of Bacterial Conjunctivitis: A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group Study in Adults and Children

(2011) Bruce E. Silverstein et al.   CLINICAL THERAPEUTICS

In vitro time-kill experiments with besifloxacin, moxifloxacin and gatifloxacin in the absence and presence of benzalkonium chloride

(2011) W. Haas et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Human aqueous humor concentrations of besifloxacin, moxifloxacin, and gatifloxacin after topical ocular application

(2011) Eric D. Donnenfeld et al.   JOURNAL OF CATARACT AND REFRACTIVE SURGERY

Challenges in Assessing Microbial Susceptibility and Predicting Clinical Response to Newer-Generation Fluoroquinolones

(2011) John Segreti et al.   JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

Safety and Tolerability of Besifloxacin Ophthalmic Suspension 0.6% in the Treatment of Bacterial Conjunctivitis

(2010) Timothy L. Comstock et al.   CLINICAL DRUG INVESTIGATION

Comparison of Besifloxacin, Gatifloxacin, and Moxifloxacin Against Strains of Pseudomonas aeruginosa With Different Quinolone Susceptibility Patterns in a Rabbit Model of Keratitis

(2010) Melissa E Sanders et al.   CORNEA

Shifting trends in in vitro antibiotic susceptibilities for common bacterial conjunctival isolates in the last decade at the New York Eye and Ear Infirmary

(2010) Adebukola Adebayo et al.   GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY

Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae

(2010) Wolfgang Haas et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Aqueous penetration of moxifloxacin 0.5% ophthalmic solution and besifloxacin 0.6% ophthalmic suspension in cataract surgery patients

(2010) Junko Yoshida et al.   JOURNAL OF CATARACT AND REFRACTIVE SURGERY

Emerging antibiotic resistance in ocular infections and the role of fluoroquinolones

(2010) Marguerite McDonald et al.   JOURNAL OF CATARACT AND REFRACTIVE SURGERY

Efficacy of Besifloxacin in an Early Treatment Model of Methicillin-Resistant Staphylococcus Aureus Keratitis

(2010) Melissa E. Sanders et al.   JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

Comparative Efficacy of Besifloxacin and Other Fluoroquinolones in a Prophylaxis Model of Penicillin-Resistant Streptococcus pneumoniae Rabbit Endophthalmitis

(2010) Erin W. Norcross et al.   JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

Efficacy and Safety of Besifloxacin Ophthalmic Suspension 0.6% in Children and Adolescents with Bacterial Conjunctivitis

(2010) Timothy L. Comstock et al.   PEDIATRIC DRUGS

Besifloxacin, a Novel Fluoroquinolone, Has Broad-Spectrum In Vitro Activity against Aerobic and Anaerobic Bacteria

(2009) W. Haas et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study

(2009) Paul Karpecki et al.   CLINICAL THERAPEUTICS

Efficacy of Besifloxacin in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus Keratitis

(2009) Melissa E Sanders et al.   CORNEA

Anti-Inflammatory Effects of Besifloxacin, a Novel Fluoroquinolone, in Primary Human Corneal Epithelial Cells

(2009) Jin-Zhong Zhang et al.   CURRENT EYE RESEARCH

Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis

(2009) Michael E. Tepedino et al.   CURRENT MEDICAL RESEARCH AND OPINION

Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli

(2009) E. Cambau et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Ocular Pharmacokinetics of Besifloxacin Following Topical Administration to Rabbits, Monkeys, and Humans

(2009) Joel W. Proksch et al.   JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

Efficacy and Safety of Besifloxacin Ophthalmic Suspension 0.6% Compared with Moxifloxacin Ophthalmic Solution 0.5% for Treating Bacterial Conjunctivitis

(2009) Marguerite B. McDonald et al.   OPHTHALMOLOGY

Ocular TRUST: Nationwide Antimicrobial Susceptibility Patterns in Ocular Isolates

(2008) Penny A. Asbell et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

Increasing prevalence of methicillin resistance in serious ocular infections caused by Staphylococcus aureus in the United States: 2000 to 2005

(2008) Penny A. Asbell et al.   JOURNAL OF CATARACT AND REFRACTIVE SURGERY

Acute bacterial conjunctivitis

(2007) Gunnar Høvding   ACTA OPHTHALMOLOGICA

Update on Bacterial Conjunctivitis in South Florida

(2007) Kara Cavuoto et al.   OPHTHALMOLOGY